D9-THC for Marijuana Addiction

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$109,761.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43DA024552-01
Award Id:
89020
Agency Tracking Number:
DA024552
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
APHIOS CORPORATION, 3-E GILL ST, WOBURN, MA, 01801
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
194643722
Principal Investigator:
TREVOR CASTOR
(781) 932-6933
APHIOS@AOL.COM
Business Contact:
() -
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): ?9-tetrahydrocannabinol (?9-THC) has been shown to alleviate marijuana withdrawal symptoms and thus has potential for treating cannabinoid dependence. However, the bioavailability of ?9-THC administered orally is poor a nd variable. In addition, it also requires drug administration several times a day. Formulations to improve bioavailability and/or to reduce dosing frequency would be expected to improve the therapeutic effectiveness of ?9-THC. In Phase I, our tech nical objectives are to develop improved oral and/or depot formulations of ?9-THC based on biopharmaceutical rationale, and select a formulation that is stable with acceptable in vitro controlled release characteristics. ?9-THC is very hydrophobic and oxyg en-sensitive, both factors that are challenges in making formulations that are orally bioavailable and stable. Utilizing proprietary SuperFluids(tm) technologies, we propose to encapsulate ?9-THC in biodegradable polymer nanospheres that will allow transpo rt to the stomach, improve its stability and enhance bioavailability. In Phase II, we will carry out pharmacological, toxicological and pharmacokinetic evaluations of the developed formulation(s). We will also provide a GMP scale-up of a stable dos age form with acceptable in vitro and in vivo bioavailability in animal models and/or in humans. Narrative: The developed controlled release, oral formulation of ?9-THC will be commercialized for treating marijuana dependence and withdrawal symptom s, cancer pain, nausea associated with cancer chemotherapy and AIDS cachexia or wasting.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government